Event Title

P-24 Attempted Synthesis & Antibacterial Pr operties of APT-6K Against NDM-1 K. pneumoniae

Location

Buller Hall 251

Start Date

3-11-2022 1:30 PM

End Date

3-11-2022 3:30 PM

Department

Medical Laboratory Sciences

Description

NDM-1 K. pneumoniae is a highly resistant bacterial organism that is capable of causing debilitating nosocomial infections in immunocompromised patients. Only “last-resort” antibiotics—such as colistin—work against this organism. Therefore, new antibiotics are needed to help fight against these types of infections. APT-6K is a novel compound that was demonstrated to be effective against MRSA with nanomolar concentrations in a prior study. Novel methods of APT-6K synthesis and its testing for antibiotic effects against NDM-1 K. pneumoniae were attempted in this research. However, APT-6K synthesis was unsuccessful. Commercially-prepared APT-6K also did not demonstrate growth inhibition against NDM-1 K. pneumoniae nor against a wild-type K. pneumoniae. Suggestions for future research are discussed.

Acknowledgments

Advisors: Melissa Poua, Medical Laboratory Sciences; Desmond Murray, Chemistry & Biochemistry

This document is currently not available here.

Share

COinS
 
Mar 11th, 1:30 PM Mar 11th, 3:30 PM

P-24 Attempted Synthesis & Antibacterial Pr operties of APT-6K Against NDM-1 K. pneumoniae

Buller Hall 251

NDM-1 K. pneumoniae is a highly resistant bacterial organism that is capable of causing debilitating nosocomial infections in immunocompromised patients. Only “last-resort” antibiotics—such as colistin—work against this organism. Therefore, new antibiotics are needed to help fight against these types of infections. APT-6K is a novel compound that was demonstrated to be effective against MRSA with nanomolar concentrations in a prior study. Novel methods of APT-6K synthesis and its testing for antibiotic effects against NDM-1 K. pneumoniae were attempted in this research. However, APT-6K synthesis was unsuccessful. Commercially-prepared APT-6K also did not demonstrate growth inhibition against NDM-1 K. pneumoniae nor against a wild-type K. pneumoniae. Suggestions for future research are discussed.